Edition:
United Kingdom

Indivior PLC (INDV.L)

INDV.L on London Stock Exchange

349.10GBp
11:30am BST
Change (% chg)

-3.60 (-1.02%)
Prev Close
352.70
Open
351.20
Day's High
353.90
Day's Low
345.20
Volume
815,400
Avg. Vol
3,012,614
52-wk High
504.60
52-wk Low
238.00

Select another date:

Tue, Jul 17 2018

Photo

Indivior warning on anti-opioid drug competition sends shares tumbling

British drugmaker Indivior warned on Wednesday it would miss its full-year profit target as its best-selling opioid addiction drug faces new competitors in the United States, sending its shares down 37 percent.

Indivior's shares soar 33 percent after U.S. court blocks sale of rival generic

Indivior Plc's shares jumped more than 33 percent on Monday after a U.S. court blocked a rival from selling a cheaper copycat of the British drugmaker's bestselling opioid addiction treatment.

Indivior's shares soar 33 percent after U.S. court blocks sale of rival generic

Indivior Plc's shares jumped more than 33 percent on Monday after a U.S. court blocked a rival from selling a cheaper copycat of the British drugmaker's bestselling opioid addiction treatment.

UPDATE 1-Indivior's shares soar 33 pct after U.S. court blocks sale of rival generic

July 16 Indivior Plc's shares jumped more than 33 percent on Monday after a U.S. court blocked a rival from selling a cheaper copycat of the British drugmaker's bestselling opioid addiction treatment.

Indivior's shares jump 30 pct after U.S. court blocks sale of rival generic

July 16 Indivior Plc's shares soared as much as 30 percent on Monday after a U.S. court blocked India's Dr.Reddy's Laboratories from selling copycat versions of the British drugmaker's bestselling opioid addiction treatment in the United States.

Indivior wins preliminary injunction against generic rival

A U.S. court has granted Indivior a preliminary injunction blocking India's Dr. Reddy's Laboratories from selling cut-price versions of the British drugmaker's best-selling opioid addiction treatment in the United States, Indivior said on Friday.

Indivior wins preliminary injunction against generic rival

A U.S. court has granted Indivior a preliminary injunction blocking India's Dr. Reddy's Laboratories from selling cut-price versions of the British drugmaker's best-selling opioid addiction treatment in the United States, Indivior said on Friday.

UPDATE 1-Indivior wins preliminary injunction against generic rival

July 13 A U.S. court has granted Indivior a preliminary injunction blocking India's Dr. Reddy's Laboratories from selling cut-price versions of the British drugmaker's best-selling opioid addiction treatment in the United States, Indivior said on Friday.

Britain's Indivior wins preliminary injuction against generic rival

July 13 A U.S. court has granted Indivior a preliminary injunction blocking India's Dr. Reddy's Laboratories from selling cut-price versions of the British drugmaker's best-selling opioid addiction treatment in the United States.

Indivior warning on anti-opioid drug competition sends shares tumbling

British drugmaker Indivior warned on Wednesday it would miss its full-year profit target as its best-selling opioid addiction drug faces new competitors in the United States, sending its shares down 37 percent.

Select another date: